| Martin L Hechanova, MD | |
|
5323 Harry Hines Blvd, Dallas, TX 75390-7208 | |
| (214) 590-4866 | |
| Not Available |
| Full Name | Martin L Hechanova |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 12 Years |
| Location | 5323 Harry Hines Blvd, Dallas, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043577380 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | P8589 (Texas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Texas Health Physicians Group | 4385535954 | 1182 |
News Archive
NANOBIOTIX, a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the U.S. Food and Drug Administration has approved its Investigational New Drug Application for NBTXR3, a first-in-class nanoparticle designed for direct injection into cancerous tumors, activated by stereotactic ablative radiotherapy (SABR) and administered in combination with an anti-PD1 antibody (nivolumab or pembrolizumab).
Bristol-Myers Squibb today announced 48-week data from an ongoing study (ETV-048) of chronic hepatitis B patients with decompensated cirrhosis, in which BARACLUDE demonstrated greater viral suppression compared to adefovir. The new BARACLUDE data were presented today at the 60th Annual Meeting of the American Association for the Study of Liver Diseases.
Celgene International Sàrl, a subsidiary of Celgene Corporation today presented results from a randomized, placebo-controlled phase II trial in patients with Behçet's disease at EULAR, the European Congress of Rheumatology annual meeting in Madrid.
In a new paper, researchers at the University of Illinois Chicago report that a drug approved for treating patients with autoimmune disease helped to prevent lung damage and death in mice infected with the SARS-CoV-2 virus, which causes COVID-19 in humans.
› Verified 8 days ago
| Entity Name | University Of Texas Southwestern Medical Center At Dallas |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972579365 PECOS PAC ID: 0648188250 Enrollment ID: O20031106000792 |
News Archive
NANOBIOTIX, a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the U.S. Food and Drug Administration has approved its Investigational New Drug Application for NBTXR3, a first-in-class nanoparticle designed for direct injection into cancerous tumors, activated by stereotactic ablative radiotherapy (SABR) and administered in combination with an anti-PD1 antibody (nivolumab or pembrolizumab).
Bristol-Myers Squibb today announced 48-week data from an ongoing study (ETV-048) of chronic hepatitis B patients with decompensated cirrhosis, in which BARACLUDE demonstrated greater viral suppression compared to adefovir. The new BARACLUDE data were presented today at the 60th Annual Meeting of the American Association for the Study of Liver Diseases.
Celgene International Sàrl, a subsidiary of Celgene Corporation today presented results from a randomized, placebo-controlled phase II trial in patients with Behçet's disease at EULAR, the European Congress of Rheumatology annual meeting in Madrid.
In a new paper, researchers at the University of Illinois Chicago report that a drug approved for treating patients with autoimmune disease helped to prevent lung damage and death in mice infected with the SARS-CoV-2 virus, which causes COVID-19 in humans.
› Verified 8 days ago
| Entity Name | Texas Health Physicians Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174573596 PECOS PAC ID: 4385535954 Enrollment ID: O20040323000759 |
News Archive
NANOBIOTIX, a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the U.S. Food and Drug Administration has approved its Investigational New Drug Application for NBTXR3, a first-in-class nanoparticle designed for direct injection into cancerous tumors, activated by stereotactic ablative radiotherapy (SABR) and administered in combination with an anti-PD1 antibody (nivolumab or pembrolizumab).
Bristol-Myers Squibb today announced 48-week data from an ongoing study (ETV-048) of chronic hepatitis B patients with decompensated cirrhosis, in which BARACLUDE demonstrated greater viral suppression compared to adefovir. The new BARACLUDE data were presented today at the 60th Annual Meeting of the American Association for the Study of Liver Diseases.
Celgene International Sàrl, a subsidiary of Celgene Corporation today presented results from a randomized, placebo-controlled phase II trial in patients with Behçet's disease at EULAR, the European Congress of Rheumatology annual meeting in Madrid.
In a new paper, researchers at the University of Illinois Chicago report that a drug approved for treating patients with autoimmune disease helped to prevent lung damage and death in mice infected with the SARS-CoV-2 virus, which causes COVID-19 in humans.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Martin L Hechanova, MD Po Box 845347, Dallas, TX 75284-5347 Ph: () - | Martin L Hechanova, MD 5323 Harry Hines Blvd, Dallas, TX 75390-7208 Ph: (214) 590-4866 |
News Archive
NANOBIOTIX, a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the U.S. Food and Drug Administration has approved its Investigational New Drug Application for NBTXR3, a first-in-class nanoparticle designed for direct injection into cancerous tumors, activated by stereotactic ablative radiotherapy (SABR) and administered in combination with an anti-PD1 antibody (nivolumab or pembrolizumab).
Bristol-Myers Squibb today announced 48-week data from an ongoing study (ETV-048) of chronic hepatitis B patients with decompensated cirrhosis, in which BARACLUDE demonstrated greater viral suppression compared to adefovir. The new BARACLUDE data were presented today at the 60th Annual Meeting of the American Association for the Study of Liver Diseases.
Celgene International Sàrl, a subsidiary of Celgene Corporation today presented results from a randomized, placebo-controlled phase II trial in patients with Behçet's disease at EULAR, the European Congress of Rheumatology annual meeting in Madrid.
In a new paper, researchers at the University of Illinois Chicago report that a drug approved for treating patients with autoimmune disease helped to prevent lung damage and death in mice infected with the SARS-CoV-2 virus, which causes COVID-19 in humans.
› Verified 8 days ago
Arthur J. Brock, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 7424 Greenville Ave, Suite 206, Dallas, TX 75231 Phone: 214-363-2004 Fax: 214-378-7483 | |
Dr. Monisha Parvin Gidvani, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 8160 Walnut Hill Ln, Suite 210, Dallas, TX 75231 Phone: 214-345-2318 | |
Dr. Enrique Pinkusiewicz, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 6546 Lyndon B Johnson Fwy, Dallas, TX 75240 Phone: 972-385-1333 Fax: 972-385-1080 | |
Dr. Dennis Rahim Abbas, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 6300 Samuell Blvd Ste 154, Dallas, TX 75228 Phone: 214-388-8898 Fax: 214-388-7898 | |
Rebecca Pedersen, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 7777 Forest Ln Ste D550, Dallas, TX 75230 Phone: 972-566-7009 | |
Clara Leigh Telford, Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 3500 Gaston Ave, Dallas, TX 75246 Phone: 214-820-2361 | |
Patrick M. Weix, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-645-0624 Fax: 214-645-0078 |